Charles River investing in expanded biologics partnership with PathoQuest

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Ca-ssis)
(Image: Getty/Ca-ssis)
Charles River Laboratories and PathoQuest have expanded their strategic partnership to help move vaccine, biologic, and gene-therapy candidates through the drug discovery and development pipeline.

“The expanded partnership with PathoQuest provides our biologics clients with access to PathoQuest’s next-generation sequencing (NGS) technology,”​ said Greg Beattie, ‎corporate vice president of global biologics testing solutions at ‎Charles River Laboratories.

PathoQuest’s technology combines a proprietary sample preparation method, equipment, and a curated pathogen database with a comprehensive BioIT analysis pipeline, Beattie explained.

The NGS solution is “a powerful test for identifying adventitious agents in a single, comprehensive analysis that minimizes false negatives while also providing a tool for the genetic characterization of cell lines,”​ he told us.

Charles River will also make a direct investment in PathoQuest as part of the expanded partnership.

“We are excited to offer our customers an industry-leading technology to help progress their vaccine, biologic and gene-therapy candidates through the drug discovery and development pipeline,”​ Beattie added.

“Working with PathoQuest, we are able to leverage our existing GLP and GMP capabilities with their NGS technology to offer a customized, fast, reliable and cost-effective solution.”

Related news

Related products

show more

lyo_development

Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers